Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$14.89 +0.5%	$18.01	$10.60 ▼ $38.12	$1.56B	0.36	1.17 million shs	881,895 shs
INDV Indivior	$11.19 -1.3%	$9.99	$7.33 ▼ $18.59	$1.54B	0.98	999,268 shs	456,476 shs
JANX Janux Therapeutics	$25.33 -2.8%	$29.16	$22.52 ▼ $71.71	$1.50B	3.24	860,384 shs	1.26 million shs
RGNX REGENXBIO	$8.18 +2.6%	$7.36	$5.04 ▼ $16.85	$409.96M	1.11	860,012 shs	2.92 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	+1.65%	-10.40%	+29.77%	-43.35%	-19.15%
INDV Indivior	+2.25%	-4.71%	+24.48%	+12.39%	-36.04%
JANX Janux Therapeutics	+1.96%	-12.52%	-9.51%	-27.83%	-46.73%
RGNX REGENXBIO	+5.98%	-18.34%	+35.31%	+8.73%	-48.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	2.8935 of 5 stars	4.4	1.0	0.0	2.7	3.3	0.0
INDV Indivior	3.3505 of 5 stars	3.6	3.0	0.0	2.6	1.7	1.9
JANX Janux Therapeutics	2.3205 of 5 stars	3.5	0.0	0.0	4.1	3.3	0.0
RGNX REGENXBIO	3.9921 of 5 stars	3.4	1.0	4.6	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.78	Moderate Buy	$40.22	170.13% Upside
INDV Indivior	3.25	Buy	$15.00	34.05% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	276.04% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	286.61% Upside

Current Analyst Ratings Breakdown

Latest RGNX, INDV, EWTX, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	EWTX Edgewise Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$41.00
4/21/2025	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$43.00 ➝ $43.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/3/2025	EWTX Edgewise Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $52.00
4/2/2025	EWTX Edgewise Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $51.00
4/2/2025	EWTX Edgewise Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$50.00 ➝ $14.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00
3/14/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.53 per share	N/A
INDV Indivior	$1.17B	1.32	$2.27 per share	4.94	N/A	∞
JANX Janux Therapeutics	$10.59M	141.55	N/A	N/A	$7.46 per share	3.40
RGNX REGENXBIO	$83.33M	4.92	N/A	N/A	$7.09 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$100.16M	-$1.55	N/A	N/A	N/A	N/A	-26.83%	-25.67%	N/A
INDV Indivior	$2M	-$0.31	N/A	6.54	N/A	-3.96%	-241.73%	15.09%	7/24/2025 (Estimated)
JANX Janux Therapeutics	-$58.29M	-$1.36	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	N/A
RGNX REGENXBIO	-$263.49M	-$4.61	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	5/14/2025 (Estimated)

Latest RGNX, INDV, EWTX, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million
3/3/2025	Q4 2024	EWTX Edgewise Therapeutics	-$0.39	-$0.42	-$0.03	-$0.42	N/A	N/A
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	26.35	26.35
INDV Indivior	N/A	0.83	0.65
JANX Janux Therapeutics	N/A	38.80	38.80
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
INDV Indivior	60.33%
JANX Janux Therapeutics	75.39%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	24.11%
INDV Indivior	N/A
JANX Janux Therapeutics	8.10%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	104.77 million	71.86 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
JANX Janux Therapeutics	30	59.17 million	37.05 million	Optionable
RGNX REGENXBIO	370	50.12 million	43.04 million	Optionable

RGNX, INDV, EWTX, and JANX Headlines

Recent News About These Companies

FDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory Application

May 13 at 7:10 PM | precisionmedicineonline.com

Regenxbio stock rises on FDA’s priority review for MPS II therapy

May 13 at 7:10 PM | investing.com

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13 at 7:05 AM | prnewswire.com

Cubist Systematic Strategies LLC Makes New $2.79 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 13 at 5:33 AM | marketbeat.com

Brevan Howard Capital Management LP Buys Shares of 41,160 REGENXBIO Inc. (NASDAQ:RGNX)

May 13 at 5:23 AM | marketbeat.com

REGENXBIO Inc.: REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 13 at 4:50 AM | finanznachrichten.de

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

May 13 at 4:50 AM | finance.yahoo.com

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

May 12 at 6:30 PM | zacks.com

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 12 at 4:05 PM | prnewswire.com

Balyasny Asset Management L.P. Has $9.18 Million Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

May 12 at 4:33 AM | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages

May 12 at 2:51 AM | marketbeat.com

Raymond James Financial Inc. Takes Position in REGENXBIO Inc. (NASDAQ:RGNX)

May 11 at 3:30 AM | marketbeat.com

Stifel Financial Corp Buys 39,564 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 10 at 3:45 AM | marketbeat.com

5RGNX : What to Expect from Regenxbio's Earnings

May 9, 2025 | benzinga.com

REGENXBIO (RGNX) Projected to Post Quarterly Earnings on Wednesday

May 9, 2025 | marketbeat.com

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

May 8, 2025 | prnewswire.com

Hsbc Holdings PLC Acquires 48,310 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

May 8, 2025 | marketbeat.com

REGENXBIO to Participate in Upcoming Investor Conferences

May 6, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Invesco Ltd.

May 6, 2025 | marketbeat.com

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

May 5, 2025 | zacks.com

PDT Partners LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, INDV, EWTX, and JANX Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$14.89 +0.07 (+0.47%)

As of 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Indivior NASDAQ:INDV

$11.19 -0.15 (-1.32%)

As of 04:00 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Janux Therapeutics NASDAQ:JANX

$25.33 -0.73 (-2.80%)

As of 04:00 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.18 +0.21 (+2.63%)

As of 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time